Abstract Number: 1392 • ACR Convergence 2022
Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Background/Purpose: During the COVID-19 pandemic, asynchronous consultations were introduced due to the significant backlog of patients with Rheumatoid arthritis awaiting clinical review. PROMs including Self-Reported…Abstract Number: 1516 • ACR Convergence 2022
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
Background/Purpose: Spondyloarthropathies (SpA) may compromise the working ability (WA) of patients, often affected by the disease during their productive life. The Work Productivity and Activity…Abstract Number: 1971 • ACR Convergence 2022
Cumulative Joint Inflammation Is Associated with Local Joint Damage Progression in Rheumatoid Arthritis Despite Long-Term Targeted Treatment
Background/Purpose: In Rheumatoid Arthritis (RA), both systemic and local disease activity have been shown to be associated with joint damage progression. Earlier we showed that…Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…Abstract Number: 0173 • ACR Convergence 2022
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
Background/Purpose: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported…Abstract Number: 0421 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis by Prior bDMARD Treatment: Analysis of a Phase 3 Trial
Background/Purpose: Prior exposure to biologic (b)DMARD therapy of patients (pts) with AS may influence treatment response.1-3 Tofacitinib is an oral JAK inhibitor for the treatment…Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…Abstract Number: 1033 • ACR Convergence 2022
Risk of Mood Disorders in SpA Patients and Correlations with Disease Activity, Quality of Life and Working Ability: Analysis of a Monocentric Cohort
Background/Purpose: Spondyloarthropathies (SpA) are chronic inflammatory arthritides, characterized by both peripheral and axial skeletal involvement and some typical extra-articular marks; they tend to associate with…Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…Abstract Number: 1544 • ACR Convergence 2022
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…Abstract Number: 2109 • ACR Convergence 2022
Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…Abstract Number: 0800 • ACR Convergence 2021
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 112
- Next Page »